About us

A lean company built on the conviction that the evidence for better medicines often already exists, unrecognised, in the scientific record.

Our history

Our predecessor entity, Myra EB Systems LLC, was formed in July 2015 as a Massachusetts limited liability company, with core operating activities commencing in 2020 following the COVID-19 pandemic. On May 6, 2026 we converted to a Delaware corporation through a merger into Myra EB Systems Inc., which succeeded to all of the business, assets, and liabilities of the predecessor.

We were founded on the belief that technology — particularly artificial intelligence — could materially reduce the inefficiencies, timelines, and escalating costs that have historically constrained drug development.

Rather than building a traditional asset-heavy biopharmaceutical organization, we have intentionally operated with a lean, capital-efficient structure, deploying equity selectively to attract experienced advisors, scientific collaborators, and strategic partners. That approach let us preserve capital while building capabilities usually associated with much larger organizations.

A bound journal volume and two loose printed pages resting on a pale surface, the text on the pages legible only as fine horizontal grain, with a single small clear glass vial standing beside them.

How we work

We operate a globally distributed model, with collaborators, advisors, consultants, and contractors across the United States, Spain, India, and other locations, supporting AI platform development, drug discovery, clinical development planning, and operational execution.

Our scientific and clinical collaboration network extends to academic medical institutions and hospital research centers across the United States and Europe, providing access to patient populations, clinical expertise, and translational research capabilities. These collaborations support IND preparation, clinical trial site identification, and the mechanistic work underlying the UNDC-005 programs.

As we advance toward IND filing and Phase 2 initiation, we expect to formally engage additional drug developers, licensing and business development professionals, and rare disease commercialization experts, in connection with and following our listing.

Management

Mr. Kumar co-founded the Company's predecessor entity in July 2015 and has served as Chief Executive Officer since inception. He brings over two decades of pharmaceutical industry experience spanning early-stage discovery through commercial launch, having worked on more than 20 clinical and commercial programs across small molecules, biologics, and gene therapies.

He spent four years at Amgen Inc., followed by ten years at Biogen Inc. in leadership and operational roles supporting product launches, contributing expertise in CMC, supply chain strategy, and commercial operations. He has provided consulting services to Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, Airway Therapeutics, Immunovant, Spark Therapeutics, and Sarepta Therapeutics, and managed the diligence process for the acquisition of an antibody asset from Almata by Avalo Therapeutics, a transaction valued at approximately $185 million. Public patent records identify Mr. Kumar as an inventor on multiple Myra-related patent applications.

Dr. Kingma has served as Chief Medical Officer and a member of the Board since 2024, having been affiliated with the Company since 2023 as Chief Medical Advisor. He is a physician-scientist with more than 20 years of experience in translational medicine and NIH-funded clinical research, has led multiple IND-to-Phase 2 programs in neonatal and rare disease, and has published more than 90 peer-reviewed papers.

He serves as Director of the Bronchopulmonary Dysplasia Center at Cincinnati Children's Hospital Medical Center and as Professor in the Department of Pediatrics at the University of Cincinnati College of Medicine, positions held since 2018. He received his M.D. and Ph.D. from Vanderbilt University in 2000, completed pediatric residency training at Cincinnati Children's in 2003, and a neonatal-perinatal medicine fellowship there in 2005.

Mr. Sharma has served as Chief Operating Officer since 2023, overseeing business development, day-to-day operations, and commercial execution of the Company's technology platform.

He previously served in a sales capacity at Adobe Inc. from 2015 to 2021, developing expertise in enterprise software commercialization and customer engagement, and was part of the early team at Shaadi.com from 2005 to 2009. He has provided consulting services to pharmaceutical and life sciences companies including Moderna, Inc. He holds an M.S. in Analytics from Bentley University and a Doctorate in Business Administration from California Southern University.

Mr. Guerin serves as Chief Financial Officer. He was previously Chief Operating Officer and Chief Financial Officer of Onconova Therapeutics (Nasdaq: ONTX), now Traws Pharma (Nasdaq: TRAW) following its 2024 merger.

As Chief Financial Officer since 2016 he led multiple public financings, including rights offerings, registered direct offerings, and at-the-market programs.

Board of directors

Governance

Within one year of the effective date of this offering, the Board will consist of at least five members, a majority of whom will be independent as defined under Nasdaq listing rules.

Mr. Jabbour serves as an independent director. He is Chairman and Chief Executive Officer of Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company, having served as Chief Executive Officer since March 2018 and as Chairman since March 2025.

He previously served as President of Matinas from March 2016 to March 2018 and as Executive Vice President, Chief Business Officer, and General Counsel from October 2013 to March 2016. Earlier roles include Executive Vice President, General Counsel, and Secretary of MediMedia USA Inc.; Senior Vice President and Head of Global Legal Affairs at Wockhardt Limited; Senior Counsel at Reliant Pharmaceuticals; and Commercial Counsel at Alpharma Inc. He began his career as a corporate associate at Lowenstein Sandler PC, and holds a B.A. from Loyola University Maryland and a J.D. from Seton Hall University School of Law.